Akèy › Limfòm Burkitt › Michigan › Ann Arbor
Etid klinik pou Limfòm Burkitt nan Ann Arbor, MI
8 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote Ann Arbor (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- C S Mott Children's Hospital, Ann Arbor
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Ap rekriteFaz 3
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Ap rekriteFaz 2
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Huron Gastroenterology PC, Ypsilanti · 7 mi lwen
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti · 7 mi lwen
- ak 4 plis
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
- C S Mott Children's Hospital, Ann Arbor
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- C S Mott Children's Hospital, Ann Arbor
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
- C S Mott Children's Hospital, Ann Arbor
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
- C.S. Mott University of Michigan, Ann Arbor
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Ap rekriteFaz 1
- University of Michigan Rogel Cancer Center, Ann Arbor
Etid Limfòm Burkitt nan lòt vil
- Houston, TX21 etid
- Milwaukee, WI16 etid
- Philadelphia, PA16 etid
- New York City, NY14 etid
- Chicago, IL14 etid
- Cincinnati, OH12 etid
- Atlanta, GA12 etid
- Seattle, WA11 etid
- Durham, NC10 etid
- Boston, MA10 etid
- Los Angeles, CA10 etid
- Aurora, CO10 etid
Lòt etid nan Ann Arbor
- Kansè pwostat27 etid
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil26 etid
- Kansè (tout kalite)25 etid
- Kansè kolorektal23 etid
- Kansè poumon23 etid
- Ensifizyans kadyak22 etid
- Leksemi mieloïd egi17 etid
- Maladi kadyovaskilè16 etid
- Kansè pankreyas14 etid
- Melanom12 etid
- Kansè renn (Kasinom selil renn)12 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.